Understanding SARS-CoV-2-Mediated Inflammatory Responses: From

Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.

A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? - The Lancet Respiratory Medicine

An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia

What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies - The Centre for Evidence-Based Medicine

Why does COVID-19 disproportionately affect older people?

PDF] The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?

Vaccines, Free Full-Text

Research Tools for Long COVID Syndrome, News & Announcements

Pulmonary surfactant-mediated inflammatory response against SARS-CoV-2